What Are Peptides?

Peptides are short chains of amino acids. That is the whole definition, and almost everything interesting about them follows from two consequences of being short.

The chemistry, briefly

Amino acids join through a peptide bond: the carboxyl group of one amino acid reacts with the amino group of the next, releasing a water molecule and leaving a covalent C–N link. Repeat this and you get a chain with a defined direction — an N-terminus at one end, a C-terminus at the other — and a specific sequence.

That sequence is the information. Twenty standard amino acids, arranged in order, produce an enormous number of possible molecules, each with its own shape, charge distribution and binding behaviour. A five-residue peptide has 3.2 million possible sequences. A fifteen-residue peptide has more possible sequences than there are stars in the observable universe.

Where the line between peptide and protein sits

There is no chemical boundary. The convention is roughly:

| | Peptide | Protein | | --- | --- | --- | | Length | Usually fewer than ~50 amino acids | Usually more than ~50 | | Structure | Often flexible, limited stable folding | Folds into a defined three-dimensional structure | | Synthesis | Can be made chemically, step by step | Usually produced biologically, in cells | | Typical role | Signalling | Structure, catalysis, transport, defence |

The distinction is real in practice even though it is arbitrary in principle, because size changes what a molecule can do and how it can be made. A 15-residue peptide can be synthesised on a machine; a 200-residue protein generally cannot.

Why the body uses peptides as signals

Short, flexible molecules make good messengers. They can be produced quickly, they bind receptors with high specificity, and — crucially — they are easy to destroy. A signal you cannot switch off is not much use as a signal.

Insulin, glucagon, oxytocin, vasopressin, GLP-1, ghrelin, GHRH: all peptides, all signals, all subject to rapid enzymatic breakdown. The body keeps them on a short leash deliberately.

Why peptide drugs are injected

Swallow a peptide and you are feeding it to a digestive system whose entire purpose is breaking peptide bonds. Stomach acid denatures it, pepsin cleaves it, pancreatic proteases finish the job, and whatever fragments survive still have to cross the intestinal wall — which large, charged molecules do poorly.

This is why the overwhelming majority of peptide drugs are given by injection, and why oral formulations, where they exist, require substantial engineering to work at all.

It is also why claims about oral or topical delivery of peptides deserve close reading. "Contains peptide X" is a statement about the contents of a container. Whether the molecule reaches any tissue where it could act is a separate question that requires separate evidence.

How peptides are studied

The research pathway is the same as for any candidate drug, and each step filters out most of what came before:

1. In vitro — cells or isolated tissue. Establishes whether the molecule interacts with a target at all.
2. Animal models — whether an effect occurs in a living system. Most compounds that work here do not work in people.
3. Phase 1 — small human studies, usually healthy volunteers, focused on safety and pharmacokinetics.
4. Phase 2 — does it do anything measurable in the target population, and at what dose?
5. Phase 3 — large randomised trials against pre-specified clinical endpoints.

Where a compound stops on that ladder is the single most useful fact about it, which is why every profile on this site states it explicitly. See how we grade evidence for the taxonomy we use.

The research landscape today

Peptide research splits into two very different worlds, and conflating them causes most of the confusion in this field.

One world contains approved peptide drugs: insulin analogs, GLP-1 receptor agonists such as semaglutide, dual agonists such as tirzepatide, and a long list of others. These have been through full development programmes with published trials and regulator-reviewed labels.

The other contains compounds like BPC-157 — synthesised, sold, widely discussed, and supported mostly by animal literature. They are not fringe science; many have genuine published research behind them. What they lack is the step where a compound is tested properly in people.

Peptide Insider covers both, and labels which is which on every page.